To target V600E, three type 1.5 RAF inhibitors (Vemurafenib, Dabrafenib, and Ecorafenib) that bind to an αC-helix-out conformation and one type 2 RAF dimer disruptor (Tovorafenib) that engages with a DFG-out conformation have been developed and applied to clinical cancer treatment 5,6. This evidence concerns the gene RAF1 and cancer.